Phase 1/2 Study of AMT-116 in Patients with Advanced Solid Tumors
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs AMT 116 Multitude Therapeutics (Primary)
- Indications Advanced breast cancer; Basal cell cancer; Biliary cancer; Bladder cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Skin cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Multitude Therapeutics
- 22 Jan 2025 New trial record